, 38 adult patients with intermediate or high-grade liposarcoma in a limb were treated by limb-sparing surgery and post-operative radiotherapy. The ten-year local recurrence-free survival was 83%, the ten-year metastasisfree survival 61%, the ten-year disease-free survival 51% and the ten-year overall survival 67%. Analysis of failure and success showed no association with the age of the patients, gender, the location of the primary tumour, the type of liposarcoma and the quality of resection.
Between December 1995 and March 2003, 38 adult patients with intermediate or high-grade liposarcoma in a limb were treated by limb-sparing surgery and post-operative radiotherapy. The ten-year local recurrence-free survival was 83%, the ten-year metastasisfree survival 61%, the ten-year disease-free survival 51% and the ten-year overall survival 67%. Analysis of failure and success showed no association with the age of the patients, gender, the location of the primary tumour, the type of liposarcoma and the quality of resection.
Our results indicate that liposarcoma may recur even ten years after the end of definitive therapy and may spread to unexpected sites as for soft-tissue sarcoma.
Liposarcoma is the most common type of softtissue sarcoma and accounts for 25% to 30% of all such cases. [1] [2] [3] [4] [5] Genetically, it is a distinct type with fatty differentiation and a common 12q amplification. Five histological variants have been described, of which well-differentiated liposarcoma is seen most often (> 50% of cases of liposarcoma). [1] [2] [3] [4] [5] Well-differentiated liposarcoma usually occurs in middle-aged or elderly patients and arises in the limbs or retroperitoneum. Myxoid and round-cell liposarcomas account for 30% to 40% of all liposarcomas, are usually diagnosed in adults and rarely in children, and tends to arise intramuscularly in the limbs. [1] [2] [3] [4] [5] Genetically, there is a supernumerary ring and giant marker chromosomes. The most frequent genetic change is translocation t(12;16)(q13;p11). Liposarcomas with a round-cell component carry a higher risk of metastasis.
The de-differentiated and pleomorphic types are relatively rare, each accounting for 5% of all cases. [1] [2] [3] [4] [5] De-differentiated liposarcoma occurs in the second half of life and arises in the limbs and the retroperitoneum. Genetically, ring or giant chromosomes similar to those of well-differentiated liposarcoma characterise this type. Microscopically, these tumours show areas of well-differentiated liposarcoma, and non-lipogenic components. The de-differentiated component may show low-grade characteristics and an indolent behaviour or may have a high-grade pattern of de-differentiation, such as in malignant fibrohistiocytoma or fibrosarcoma, and a high risk for distant metastases. Pleomorphic liposarcoma occurs in elderly patients, and is located in the limbs and the retroperitoneum. Cytogenetically, there is a complex structural rearrangement. This type has a high risk of local recurrence and systemic spread. The mixed-type liposarcoma is a rare variant, which shows a combined myxoid or round-cell appearance with well-differentiated and pleomorphic components. [1] [2] [3] [4] [5] Nowadays, all liposarcomas and other types of soft-tissue sarcoma are treated by limbsparing surgery, when confined to the limbs preceeded or followed by radiotherapy, with or without chemotherapy. 6 In most cases, this has replaced the radical surgical approach for treating sarcomas of the limbs. The most important factor which determines the feasibility of limb-sparing surgery is resectability of the tumour as assessed clinically and radiologically. Induction chemotherapy or radiotherapy may facilitate resection, and may also play a role in controlling the disease. Postoperative chemotherapy is still in the experimental stage, but may be used in selected cases. 6 Follow-up is usually carried out for life and is aimed at the diagnosis of salvageable relapse and the detection of late local complications or the systemic effects of primary treatment.
In this series, we report our experience of the treatment of intermediate or high-grade liposarcomas affecting adults and arising in the limbs. This is a homogeneous population which was diagnosed by one pathologist (JI) THE JOURNAL OF BONE AND JOINT SURGERY and a radiologist (not an author), treated by one team of dedicated orthopedic surgeons (YK, JB, IM) and one of two sarcoma-experienced oncologists (OM, VS), with regular follow-up by the same team.
Patients and Methods
Between December 1995 and March 2003, 38 consecutive adult patients (20 men, 18 women) with a mean age of 51.1 years (18 to 84) with a liposarcoma confirmed by histological examination of a CT-guided core needle biopsy confined to a limb, were treated at our institution. The mean follow-up was 67 months (9 to 123). The site of the primary sarcoma was the thigh in 26 patients, the lower leg in four, the arm in two, the popliteal fossa in two, and one each in the buttock, the forearm, the shoulder and the sole of the foot. The subtype of the liposarcoma was myxoid in 21, round-cell in 13 and pleomorphic in four. Intermediategrade liposarcomas, including myxoid liposarcomas, were treated in the same way as high-grade tumours. There were no low-grade, well-differentiated liposarcomas. The Union International Contre le Cancer (UICC)-(Tumour, nodes and metastases (TNM) 2002) sarcoma stage was IA in one patient, IIA in two, and IIB in 35. 7 All the patients were candidates for the limb-sparing approach. In none was amputation thought to be the procedure of choice.
Informed consent was obtained from each patient before any diagnostic procedure, surgical intervention, radiotherapy, chemotherapy or isolated limb perfusion.
Only patients with a high-grade UICC (TNM 2002) IIB lesion adjacent to the neurovascular bundle or bone, with no serious systemic illness, were considered to be candidates for induction therapy. Those with similar lesions, especially in the lower limb, who were considered poor candidates for systemic induction chemotherapy because of comorbidities, were referred for isolated limb perfusion with tumour necrosis factor alpha (TNF-α) and melphalan. This method has been described in detail elsewhere. 8, 9 Briefly, a bolus of 4 mg of recombinant TNF-α is injected into the lower limb, followed 30 minutes later by an injection of 1.5 mg/kg body-weight of melphalan. The temperature of the perfused limb is maintained at 39˚C to 40˚C during the entire procedure. Limb-sparing surgery was carried out six to eight weeks after isolated limb perfusion. No systemic adjuvant chemotherapy was given. As an alternative to isolated limb perfusion in patients with good mobility and general health, pre-operative chemotherapy was suggested. The protocol consisted of three, three-weekly identical cycles of adriamycin and ifosfamide. Adriamycin was infused at a dose of 75 mg/m 2 /day on day 1 over 15 minutes and ifosfamide at 3.0 g/m 2 /day on days 1 to 2 by central intravenous infusion. Mesna was given at a dose of 3.0 g/m 2 /day on days 1 to 2 and half the dose on day 3. A subcutaneous injection of 5 mcg/kg of granulocyte colonystimulating factor (G-CSF; Neupogen; Hoffman La Roche, Basel, Switzerland) was given daily, starting 24 hours after chemotherapy. Adjuvant chemotherapy consisted of three, three-weekly cycles of adriamycin and ifosfamide at the same schedule as in the pre-operative treatment only if the pathologist had reported a favourable response to chemotherapy.
The surgical specimen was studied for the adequacy of resection, the percentage of necrosis within the tumour, and the presence of vascular invasion by the tumour.
Limb-sparing surgery was attempted in all the patients by the same surgical team. In those who had undergone an attempt at down-staging by pre-operative chemotherapy, the operation was performed one to two weeks after the last course of chemotherapy. Pre-operative evaluation also included MRI of the involved limb, CT of the chest, a multiple gated acquisition scan and a full blood count and biochemical analysis. Several patients were referred from other centres where they had undergone an excisional biopsy, limited or inadequate surgery (termed as 'first surgical attempt') for a wide local resection (second attempt) and adjuvant therapy. In other cases in which our first limbsparing surgery had inadequate margins, a second attempt with a wide local resection was carried out.
In all the cases, the pathologist (JI) reviewed the diagnostic material before making a decision on the surgical and oncological approach. Fresh specimens from the limbsparing procedures were obtained and examined by the same pathologist and reviewed by all the other members of the team. Macroscopic pictures of the specimen and its cut section were taken. The size of the liposarcoma, the surgical margins, the presence of tumour necrosis, haemorrhage, formation of a cyst, fibrosis or calcification and vascular invasion were studied and documented. In cases of limbsparing surgery after neo-adjuvant therapy two slices from the largest diameter of the tumour mass at the maximal sagittal and tangential cross-sections were entirely embedded in paraffin and histologically examined by a mapping technique. 10 Surgical margins of at least 1.0 cm to 1.5 cm were considered to be adequate (R0), 0.0 cm to 0.99 cm to be marginal (Rm), and if tumour was present at the inked edge to be involved (R1). A good response to pre-operative chemotherapy or isolated limb perfusion with TNF-α was defined when the percentage of necrosis was more than 90. All the other cases were said to have a poor response.
All the patients in our series received post-operative radiotherapy. The same team of two radiation oncologists (OM, VS), using a Phillips Simulator (Royal Phillips Electronics, The Netherlands), carried out pre-treatment simulation. Radiotherapy was delivered through an 8 MV linear accelerator photon beam to the target volume by two opposing fields, in a schedule of 1.8 Gy/fraction, five fractions per week to a midplane dose of 63 Gy or 70 Gy in the case of marginal excision or involved margins. Field resimulation for verification was carried out in each case after 25 Gy. An initial midplane dose of 45 Gy was given to the tumour bed according to a pre-operative imaging study and, as marked by the surgical clips, to the surgical scar. Field borders were either the whole compartment, or prox-imal and distal margins of 10 cm in non-compartmental lesions. A coned-down field (by re-simulation) of a 5 cm margin proximally and distally received a dose up to 54 Gy, and a further re-simulated coned-down field of the tumour bed plus a 2 cm margin received a dose of up to 63 Gy or 70 Gy. The surgical scar and the target volume of the limb were exposed, when feasible, to two opposed tangential fields. In this way, the skin received the full dose of radiotherapy. If the beam had been targeting the limb and scar in a perpendicular way, the skin would have received a sub-optimal dose due to the large skin-sparing effect of a 8 MV photon beam. In cases in which the scar had to be irradiated by a perpendicular beam, a wax bolus 1 cm thick and 4 cm wide covered the surgical scar. Interruption of radiotherapy for acute skin and soft-tissue toxicity was compensated for by the addition of radiation according to the time, dose and fractionation (TDF) values.
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The follow-up included a detailed history, physical examination, measurement of the full blood count and serum lactate dehydrogenase (LDH) every three months, plain radiography of the chest every three months, and CT of the chest and limb every six months, for the first two years. Over the next three years a detailed history, physical examination, measurement of the full blood count and serum LDH, CT of the chest and MRI or CT of the limb were performed every six months. Further radiological studies were carried out on the basis of symptoms and clinical impression. Statistical analysis. This was performed using the two-bytwo test and Kaplan-Meier survival analysis. Overall survival was calculated from the date of positive tissue diagnosis until the date of death. Only the disease-specific deaths were considered for statistical analysis.
Disease-free survival was calculated from the date of definitive surgery, whether carried out primarily or after pre-operative treatment, until the date of the first recurrence. Similarly, survival free from metastasis and from local recurrence were calculated from the date of definitive surgery to the date of the event.
Results
Doxorubicin-based induction chemotherapy was administered in 13 patients, induction isolated limb perfusion/ TNF-α in four and no induction therapy in 21. All the patients underwent limb-sparing surgery followed by radiotherapy. The degree of necrosis of the sarcoma after induction therapy was 95% in four patients (3 chemotherapy, 1 TNF-α), 90% to 60% in seven, and 50% or less in four. A first attempt at resection was performed either in the referral centre or, less often, in our centre. The margins of resection at the first attempt were wide and adequate in ten patients, marginal in three, and involved in 25. The 28 patients with less than adequate margins at the first attempt were wide in 13, marginal in 12 and involved in three at the second attempt. The time interval between the first attempt at surgery and the start of post-operative radiotherapy ranged between 1.3 and 6.9 months (median 2.9). The longer intervals stemmed mainly from the need to administer adjuvant chemotherapy before radiotherapy, and less often from delayed wound healing. All the patients received radiotherapy as planned. Late effects of radiotherapy included pain (severe in four patients, moderate in nine, mild in 13 and none in 12), neuromotor disturbance (severe in 3, moderate in 6, mild in 8 and none in 21), joint stiffness in six patients where the joint was adjacent to the tumour bed, soft-tissue damage (stony-hard induration in 6, moderate stiffness in 7, mild in 12 and none in 13), chronic lymphoedema in eight, radiation-related fracture in two, arterial insufficiency in one with known peripheral vascular disease, chronic ulceration requiring treatment with a free flap in one and severe infection necessitating amputation in one.
Local recurrence was observed in six patients and metastatic disease in ten. The sites of the first recurrence were the lung in three, soft tissues of the neck in one, the thyroid in one, the retroperitoneum in two, the heart in one, the spine in one and the soft tissue and liver in one. The ten-year local recurrence-free survival was 83%, the ten-year metastasisfree survival 61%, the ten-year disease-free survival 51% and the ten-year outcome survival 67%. The median values of these parameters have not been reached as yet (Fig. 1) .
Analysis of failure and success in terms of the local and distant recurrence-free survival, disease-free survival and overall survival showed no association with the age of the patient (at cut-off points of 40, 50 and 60 years of age), gender, the location of the primary tumour (upper vs lower limb), the type of liposarcoma (myxoid liposarcoma vs non-myxoid liposarcoma) and the quality of resection (positive or marginal resection vs wide margins).
Discussion
The results achieved in our series are comparable with those reported in the literature for heterogeneous populations of soft-tissue sarcoma and homogeneous populations of specific histological types such as malignant fibrohistiocytoma treated by limb-sparing surgery and radiotherapy. [12] [13] [14] We believe that this is the first report of a homogeneous series of limb liposarcoma treated similarly by a single centre.
Our results point to several important issues of local recurrence, systemic recurrence, disease-free survival and overall survival. The period of risk for local recurrence is the first three years after definitive surgery. Thereafter, there were no further local relapses. Systemic recurrence may occur even ten years after definitive surgery and after radiotherapy. The disease-free survival curve reflects the summation of local and systemic spread. The overall survival curve seems to be more optimistic than the disease-free survival curve because several events of systemic recurrence may be treated and even cured. Surprisingly, we could find no link between the patients' characteristics, the type of tumour and the quality of resection and the outcome in terms of the local recurrence-free survival, metastasis-free survival, disease-free survival and overall survival. The most important finding was the lack of influence of the margins of resection on the local control of the disease. This observation emphasises the importance and efficacy of the radiotherapy. While negative margins are generally required in soft-tissue sarcoma in order to have satisfactory local control and postoperative radiotherapy cannot compensate for inadequate margins, in liposarcoma, according to our experience, the situation was different. Radiation therapy achieved good local control even in patients with positive margins.
The European Society of Medical Oncology (ESMO) minimum clinical recommendations for diagnosis, treatment and follow-up of soft-tissue sarcoma have recently been published. 15 The issue of follow-up is very clear: "Early detection of recurrence might influence the possibility of a curative treatment. The patient should be followed every three months with history and physical examination. MRI of the site of resection of the primary tumour is proposed twice a year for the first two to three years and then once a year. For patients with high-grade tumours, a chest radiograph is recommended every three to four months in the first two to three years, twice a year up to the fifth year, and once a year thereafter". 15 The importance of the follow-up was well described in the International Sarcoma Meeting in Stuttgart. 16 It was claimed that follow-up in patients with soft-tissue sarcoma is essential for several reasons. The most important aim of a thorough follow-up is the early diagnosis of treatable, resectable and potentially curable recurrences, either localised or systemic. Local recurrence after limb-sparing surgery, or stump recurrence after amputation, may be excised and sometimes re-irradiated, by teletherapy or by brachtherapy. Pulmonary metastases, for instance, especially when single, can be resected, and the patient can re-achieve the status of no evidence of disease. Brain metastases, although infrequent in soft-tissue sarcoma, may be resected and irradiated. The second aim of follow-up is the detection and treatment of therapy-related late complications such as lymphoedema, pain, loss of muscular function because of fibrosis, chronic wounds, vascular problems, weakening of bone and fractures. These events are not uncommon and have considerable influence on the patients' quality of life.
Three important points have not been referred to in the ESMO guidelines. The first is the difference in approach to the various types of soft-tissue sarcoma. All histological types of soft-tissue sarcoma of the limb are treated in the same way by surgery, radiotherapy, with or without neoadjuvant or adjuvant chemotherapy. There is no difference in the recommendations for follow-up. Liposarcomas and malignant fibrohistiocytoma, or fibrosarcomas, are followed by the same protocol of survey of the primary site and lung. According to our experience, liposarcoma may recur locally and in the lungs, but also in the bones, other uncommon sites such as the lymph nodes, soft tissues, spine, retroperitoneum, and even in the thyroid. The unpredictable spread of liposarcoma seems to be a characteristic feature of this tumour, in contradiction to malignant fibrohistiocytoma, 17 which tends to recur during the first two years. A whole-body CT scan may reveal new sites of spread, but practically, a repeated routine whole-body scan may not be feasible. Clinical awareness of this phenomenon should be kept in mind.
The second issue is the duration of follow-up. Follow-up for five years may suffice for most soft-tissue sarcomas, as reported by our group in cases of malignant fibrohistiocytoma, 17 because late events are very uncommon. However, in liposarcomas, a follow-up for five years is not sufficient and should be for at least ten years, with biannual visits. In this series, the time-to-failure curve did not reach a plateau even after follow-up for ten years because recurrences continued to occur.
The third issue, although not studied and not reported in our series, but which may be relevant for all types of softtissue sarcoma, is the need for screening for second and even third primary malignancies. A second malignancy may be the late result of chemotherapy and radiotherapy used for the primary soft-tissue sarcoma. We have already found that patients with soft-tissue sarcoma tend to develop multiple malignancies, half of which occur after the diagnosis of the soft-tissue sarcoma, independently of the previous therapies. 18 Briefly, 10% to 12% of patients with soft-tissue sarcoma, including liposarcoma, develop a second primary malignancy before or after the diagnosis of sarcoma. 18 The practical point of this observation is that planned, routine and active screening for a second primary malignancy should take place during the first five years of follow-up. For example, mammography, colonoscopy, gynaecological examination, rectal examination, with or without measurement of prostatic specific antigen, should be carried out meticulously. The question as to whether a retroperitoneal liposarcoma in one of our patients was a metastasis of a previous limb liposarcoma of the same histological pattern 19 or represented a second primary soft-tissue sarcoma, remains to be elucidated.
Liposarcomas tend to recur even at late intervals after treatment at unexpected sites. Patients with liposarcomas need long-term follow-up in order to diagnose late recurrences, and late therapy-related side-effects and should be screened for a second malignancy.
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